Acronym:
NEOCREATE
ACTRN/NCT /ethics:
Scientific title:
Summary of trial and patient characteristics
Cancer Type | Stomach & Oesophageal | ||
---|---|---|---|
Trial Type | Treatment | ||
Phase | Phase II | Tumour Stream | Oesophageal Cancer |
Age Range | 18 years and older | Cancer Stage | Clinical Trials - Cancer Stage |
Sex | Both | Anticipated Start Date | |
Molecular Target | Anticipated End Date |
Cancer Type | Stomach & Oesophageal |
---|---|
Trial Type | Treatment |
Phase | Phase II |
Age Range | 18 years and older |
Sex | Both |
Molecular Target | |
Tumour Stream | Oesophageal Cancer |
Cancer Stage | Clinical Trials - Cancer Stage |
Anticipated Start Date | |
Anticipated End Date |
Trial Summary
AR is a single-arm, multi-centre, open-label, phase-II clinical trial with safety run in neo-adjuvant chemo-radiotherapy plus immunotherapy with avelumab (carboplatin paclitaxel-RT-Avelumab) in operable oesophageal/OG) adenocarcinoma
Lay Summary
Sponsor / Cooperative group
Participating Hospitals
Hospital | Clinical Trial Coordinator | Phone | Principal Investigator | Recruitment Status | |
---|---|---|---|---|---|
Flinders Medical Centre | Alex Scott-Hoy | alex.scott-hoy@sa.gov.au | 08 8204 4830 | Amitesh Roy | Recruitment on Hold |